Jenburkt Pharmaceuticals Ltd
NSE: BSE: 524731
₹1004
(0.93%)
Tue, 10 Mar 2026, 04:28 am
Market Cap4.43B
PE Ratio13.67
Dividend1.79
Health Technology
Pharmaceuticals: Major
24.5KJenburkt Pharmaceuticals Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (3.7x coverage).
- Jenburkt Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Jenburkt Pharmaceuticals's dividend is above the markets top 25% of dividend payers in India (3.08%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
health
- Jenburkt Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Jenburkt Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Jenburkt Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (272%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 18.3x debt.
- Jenburkt Pharmaceuticals's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (8.9% vs 6.2% today).
- Jenburkt Pharmaceuticals earns more interest than it pays, coverage of interest payments is not a concern.
- Jenburkt Pharmaceuticals's level of debt (6.2%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Jenburkt Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Ashish's compensation has been consistent with company performance over the past year, both up more than 20%.
- Ashish's remuneration is higher than average for companies of similar size in India.
misc
- Jenburkt Pharmaceuticals is not covered by any analysts.
- Jenburkt Pharmaceuticals has significant price volatility in the past 3 months.
past
- Jenburkt Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.
- Jenburkt Pharmaceuticals used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Jenburkt Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Jenburkt Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Jenburkt Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Jenburkt Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- Jenburkt Pharmaceuticals is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Jenburkt Pharmaceuticals is good value based on earnings compared to the India market.
- BSE:524731 is up 12.3% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524731 is up 12.3% outperforming the market in India which returned 8% over the past month.
- Jenburkt Pharmaceuticals's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Jenburkt Pharmaceuticals's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Jenburkt Pharmaceuticals is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- 524731 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524731 underperformed the Market in India which returned -14.5% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800